Semax vs Selank

How they differ

Each row below repeats what the two profiles cite. It is not a ranking or a recommendation.

Side by side

TopicSemaxSelank
What it is

A synthetic peptide of seven amino acids, designed from a fragment of adrenocorticotropic hormone (ACTH) without that hormone’s hormonal effects.1

A synthetic heptapeptide, Thr-Lys-Pro-Arg-Pro-Gly-Pro, according to FDA’s substance registry.4

FDA status

Not FDA-approved

Not an FDA-approved drug1

Not FDA-approved. FDA staff recommended in May 2026 against adding Semax to the 503A compounding list, and FDA has not issued a final rule. Under an October 30, 2026 HHS draft enforcement-discretion policy, Semax free base is one of six listed peptides; HHS says it does not intend to take enforcement action against licensed pharmacies, federal facilities or physicians that compound it under the policy’s conditions.1,3,5

Is Semax FDA-approved?

Not FDA-approved

No FDA approval reported; FDA lists safety concerns from a withdrawn compounding nomination2

No FDA approval is reported in the sources reviewed here. FDA’s compounding safety-risk page lists selank acetate among withdrawn nominations with possible safety risks.2

Is selank FDA-approved?

HHS compounding policy, October 30, 2026

In the policy: one of the six peptides it lists.3

Not among the six peptides the policy lists.3

HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Selank is not among them.3,5

FDA compounding safety-risk page

Listed.

FDA’s compounding safety-risk page, last updated April 22, 2026, lists Semax among substances whose nominations were withdrawn and says FDA lacks enough information to know whether it would cause harm in people.2

Listed.

FDA’s compounding safety-risk page, current as of April 22, 2026, lists selank acetate among bulk drug substances that were in category 2 before their nominations were withdrawn, citing possible immune reactions from aggregation and impurities.2

Kinds of studies cited

Limited human data

  • Small, short, or incompletely reported human study A 1996 study without a control group or blinding in 37 adults with migraine or facial nerve pain. Four of 12 migraine patients reported that their headache stopped, and patients with typical trigeminal neuralgia showed no change in pain.1
  • Small, short, or incompletely reported human study A 2002 meeting abstract on people with chronic reduced blood flow to the brain that did not report the number of patients or clinical outcomes.1
  • Small, short, or incompletely reported human study Other reports FDA found in healthy adults, adults with peptic ulcer, and children with depression or tics. Several are meeting abstracts, most did not discuss side effects, and in some Semax was given alongside other treatments.1
  • Animal or laboratory research Rodent studies reporting nerve-protective, anti-clotting, pain-relieving and antidepressant-like effects through mechanisms FDA describes as poorly understood.1

Limited human data

  • Small, short, or incompletely reported human study A 2015 Russian study of 70 patients with anxiety disorders comparing phenazepam alone (30 patients) with phenazepam plus selank (40 patients). The abstract does not describe how patients were assigned to the groups.6
  • Animal or laboratory research A 2017 rat study reporting that selank reduced anxiety-like behaviour in a maze test, alone and combined with diazepam, under chronic mild stress.7
Records collected

0 ClinicalTrials.gov records and 40 PubMed records collected

0 ClinicalTrials.gov records and 13 PubMed records collected

Area of study

Brain, nerves and sleep1

Brain, nerves and sleep7

Latest dated events
  1. HHS publishes notice of a draft enforcement-discretion policy whose Appendix A lists Semax among six peptide substances used in compounding.3,5
  2. FDA’s Pharmacy Compounding Advisory Committee discusses Semax.8
  3. FDA staff date their evaluation recommending that Semax not be added to the 503A bulks list.1
  1. FDA’s compounding safety-risk page, as last updated, lists selank acetate among withdrawn nominations with possible safety risks.2
  2. A rat study of selank under chronic mild stress is published.7
  3. A Russian clinical study of selank added to phenazepam in anxiety disorders is published.6

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Citations

Sources

Coverage and sources →

Numbered markers in the text point here. Each link opens the original public record.

  1. 1
    FDA briefing document for Semax ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  2. 2
    Certain bulk drug substances for use in compounding that may present significant safety risks ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  3. 3
    HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗

    U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  4. 4
    Selank substance identity record ↗

    FDA Global Substance Registration System · Official source · Source checked November 15, 2026

  5. 5
    Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 ↗

    Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  6. 6
    Optimization of the treatment of anxiety disorders with selank (2015, in Russian) · PMID 26356395 ↗

    Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova · Official source · Source checked November 16, 2026

  7. 7
    Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats (2017) · PMID 28280289 ↗

    Behavioural Neurology · Official source · Source checked November 15, 2026

  8. 8
    July 23-24, 2026 Pharmacy Compounding Advisory Committee meeting ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026